Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.58 |
| ▸ | TNF | P01375 | 1/20 | 0.58 |
| ▸ | NPC1 | O15118 | 1/20 | 0.51 |
| ▸ | TP53 | P04637 | 2/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | ACSS2 | Q9NR19 | 6/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15560601 | 0.82 | TSHR (0.67) | TSHRTNFNPC1TP53MAPK1 | |
| SCHEMBL16756333 | 0.79 | TSHR (0.64) | TSHRTNFNPC1TP53MAPK1 | |
| SCHEMBL30582653 | 0.75 | TSHR (1.00) | TSHRTNFNPC1TP53MAPK1 | |
| SCHEMBL16756579 | 0.75 | TSHR (1.00) | TSHRTNFNPC1TP53MAPK1 | |
| SCHEMBL16756578 | 0.75 | TNF (0.62) | TSHRTNFNPC1TP53MAPK1 | |
| SCHEMBL15560565 | 0.72 | TSHR (0.72) | TSHRTNFNPC1TP53MAPK1 | |
| SCHEMBL28860552 | 0.66 | AGTR1 (0.50) | TSHRTNFTP53MAPTACSS2 | |
| SCHEMBL22420480 | 0.65 | TNF (0.59) | TSHRTNFNPC1TP53MAPK1 | |
| SCHEMBL15552030 | 0.65 | TSHR (0.77) | TSHRTNFNPC1TP53MAPK1 | |
| SCHEMBL2079176 | 0.64 | FGFR1 (0.46) | NPC1TP53MAPTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2858983-B1 | TNF-ALPHA MODULATING BENZIMIDAZOLES | UCB BIOPHARMA SPRL (BE) | 2018-04-18 | — | — | EP | disclosed |
| US-9550737-B2 | TNF -α modulating benzimidazoles | UCB BIOPHARMA SPRL (BE) | 2017-01-24 | — | — | US | disclosed |
| US-20150152065-A1 | TNF -Alpha Modulating Benzimidazoles | UCB BIOPHARMA SPRL (BE) | 2015-06-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150152065-A1 | TNF -Alpha Modulating Benzimidazoles | TNF, TNFRSF1A, NFKBIA | TSHR 1696/4885TNF 1/4885NPC1 3216/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.